HS-10352 / Jiangsu Hansoh Pharma - LARVOL DELTA

A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients (clinicaltrials.gov) - P1/2 | N=52 | Not yet recruiting | Sponsor: Henan Cancer Hospital

New P1/2 trial • Breast Cancer • Oncology • Solid Tumor

HS-10352 in hormone receptor-positive, HER2-negative advanced breast cancer: A phase 1 dose-escalation trial. (PubMed, Cancer Med) - P1 | "HS-10352 at 6 mg QD was well-tolerated in patients with HR-positive, HER2-negative ABC, and showed preliminary antitumor activity in patients with PIK3CA mutated tumors. These findings support the further clinical development of HS-10352."

Journal • Metastases • P1 data • Breast Cancer • Diabetes • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA

First-in-human dose-escalation study of the phosphatidylinositol 3-kinase α-selective inhibitor HS-10352 in advanced breast cancer (AACR 2022) - P1 | "HS-10352 showed a manageable safety profile and favorable PK properties. The promising antitumor activity was observed in patients with HR+HER2- advanced breast cancer harboring PIK3CA mutation."

P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=224 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Combination therapy • New P1 trial • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA

Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Trial completion date: Aug 2022 ➔ Aug 2023 | Trial primary completion date: Apr 2021 ➔ Apr 2023

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • HER-2

Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer (clinicaltrials.gov) - P1; N=54; Recruiting; Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Clinical • New P1 trial • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor